Allergic rhinitis in children, with or without comorbid asthma. Vasomotor and allergic rhinitis
Conditions
Interventions
Intervention 1: Intervention group: Participants receive 0.65% sodium chloride nasal spray (isotonic saline) in addition to routine care (cetirizine, montelukast, or seroflo as clinically indicated).
Sponsors
Oroumia University of Medical Sciences
Eligibility
Sex/Gender
All
Age
6 Years to 18 Years
Inclusion criteria
Inclusion criteria: Age 6 to 18 years Diagnosis of moderate to severe allergic rhinitis according to the ARIA 2019 guidelines and an allergist with typical symptoms including sneezing, clear nasal discharge, nasal congestion, and nasal itching Diagnosis of moderate to severe asthma based on spirometry (FEV1/FVC ratio less than 60% and =12% improvement in FEV1 with an absolute increase of =200 ml after salbutamol administration) Written parental consent to participate in the study No diagnosis of cardiac or pulmonary diseases other than asthma, chronic pneumonia, and immunodeficiency No non-allergic nasal congestion such as non-allergic rhinitis, nasal polyps, deviated septum, and concha bullosa
Exclusion criteria
Exclusion criteria: Disagreement to continue participating in the study Development of new diseases affecting the treatment process during the study Bleeding or other complications during treatment Sensitivity to the medication or any medical condition that requires discontinuation of treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Total Nasal Symptom Score (TNSS) in children with allergic rhinitis. Timepoint: Measured at baseline (before intervention) and after 4 weeks of intervention. Method of measurement: Standardized Total Nasal Symptom Score (TNSS) questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in asthma severity score. Timepoint: Baseline (before intervention), 2 weeks, and 4 weeks after intervention. Method of measurement: Pediatric Asthma Severity Score, assessed by standardized clinical examination and history (including wheeze, use of accessory respiratory muscles, and expiratory prolongation) using a structured data collection form. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contact??Dr. Hamid Reza Houshmand
Oroumia University of Medical Sciences
Outcome results
None listed